Zag Bio

Tolerance Bio, Inc.

This biopharmaceutical company develops thymus-based therapies to treat immune-mediated diseases including cancer, autoimmunity and transplant rejection for patients requiring restored immune tolerance.

Candid Therapeutics

This clinical-stage biotechnology company develops T-cell engager antibodies for patients with autoimmune and inflammatory diseases.

Thymmune

This biotechnology company develops scalable thymic cell therapies to restore immune function for patients with immunodeficiencies, autoimmune disorders, and transplant-related conditions.

Re-Aim Therapeutics

This early-stage biotechnology company develops antibody-based therapies that target and deplete disease-causing cells to treat patients with autoimmune and inflammatory disorders.

SEITO Biologics AG

This biotechnology company develops selective regulatory T cell engagers to treat patients suffering from autoimmune diseases, chronic inflammation and organ transplant rejection.

Egle Therapeutics

This biotechnology company develops precision medicines that modulate regulatory T cells to treat patients with autoimmune diseases and cancer.

Enthera Pharmaceuticals

This biotech company develops monoclonal antibodies and fusion proteins for patients with autoimmune conditions including type 1 diabetes and inflammatory bowel disease.

Ouro Medicines

This biotechnology firm develops T-cell engager therapies to treat patients living with chronic immune-mediated diseases.